News
The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.
The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.
The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.
Patients with eosinophilic esophagitis in the US have high health care resource utilization costs, according to a retrospective national claims study.
While CVS hospitalizations have declined, the illness continues to present among young women, Black individuals, and leads to high costs among Hispanic patients.
Subcutaneous infliximab therapy alone is associated with higher immunogenicity than IV infliximab and an immunomodulator combined.
Janus kinase (JAK) inhibitors are not associated with an increased risk for gastrointestinal perforation (GIP) among patients with rheumatoid arthritis (RA), according to study results published in ...
Adding perioperative systemic therapy to CRS-HIPEC can improve some outcomes in patients with resectable colorectal peritoneal metastases, data suggest.
Providers favor CPAP and patients prefer tirzepatide for treatment for comorbid obesity and obstructive sleep apnea.
Sociodemographic disparities, such as low income and lack of health insurance, contribute to reduced CRC screening at age 45 years.
Ambulatory acute kidney injury is common among individuals with cirrhosis and is associated with a high 90-day mortality.
The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results